Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy By Ogkologos - March 9, 2026 321 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from multiomic profiling in the CITN-12 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... May 15, 2019 Ensuring a Smooth Leadership Transition at NCI April 10, 2019 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... June 14, 2026 Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant... July 22, 2021 Load more HOT NEWS Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in... EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan Foodie Fridays: Watermelon Salad The American Society of Clinical Oncology and the American Cancer Society:...
